Fractal’s Trial Run: Elevating Retail Excellence at Microsoft Innovation Hubs

Jul 9, 2024

We are thrilled to announce a significant milestone in our partnership with Microsoft. Fractal’s retail business experiments solution, Trial Run, is now featured as a self-standing demo at all Microsoft Innovation Hubs globally. We are proud to stand alongside Microsoft’s and other leading partners’ technologies, showcased in over 40 Hubs across the Americas, Europe, Asia, and Australia.

Trial Run is an Azure-based SaaS solution for in-store, in-market, and shopper-focused business idea testing. Powered by AI and advanced analytics, it delivers unique, actionable, and statistically significant insights that can empower retailers’ various business functions.

Trial Run enables retailers to build, develop, and scale their experimentation capabilities efficiently and affordably. It also allows businesses to make informed, data-backed decisions on pricing, promotions, and merchandising.

We invite retailers to experience firsthand Trial Run capabilities under the guidance of Microsoft’s Technology Architects during their next Hub visit.

Together, let’s shape the future of retail, one experiment at a time.

Learn more about Trial Run on Azure Marketplace.

Disclaimer

Fractal Analytics Limited (the “Company”) is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of our Company at Fractal Analytics, the SEBI at www.sebi.gov.in as well as on the websites of the BRLMs, and the websites of the stock exchange(s) at ww.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see “Risk Factors” of the RHP, when available. Potential investors should not rely on the DRHP for any investment decision.

Disclaimer